|
Dario Carlo Altieri, M.D., is a researcher who works as director of The Wistar Institute Cancer Center in Philadelphia.〔(【引用サイトリンク】url=http://www.wistar.org/news-and-media/press-releases/cancer-biologist-dario-altieri-lead-the-wistar-institute-cancer-center )〕 In 2015, he became the CEO of The Wistar Institute.〔(【引用サイトリンク】url=http://www.upenn.edu/almanac/volumes/v61/n24/dario-altieri-wistar.html )〕 His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.〔(【引用サイトリンク】url=http://wistar.org/our-science/scientists/dario-c-altieri-md )〕〔(【引用サイトリンク】url=http://www.jci.org/articles/view/45471 )〕〔(【引用サイトリンク】url=http://archive.sciencewatch.com/dr/erf/2009/09junerf/09junerfAlti/ )〕 Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells. In 2013, Altieri and his team received a $1.5 million grant from the Department of Defense to prepare the drug for human trials.〔(【引用サイトリンク】url=http://wistar.org/news-and-media/press-releases/Gamitrinib_DoD_Grant )〕〔(【引用サイトリンク】url=http://www.biotechdaily.com/genomics_proteomics/articles/294722285/combinatorial_drugs_target_cancer_cell_mitochondria.html )〕 Prior to joining Wistar, Altieri was the founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School. He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.〔(【引用サイトリンク】url=http://www.wistar.org/news-and-media/press-releases/cancer-biologist-dario-altieri-lead-the-wistar-institute-cancer-center )〕 == Select publications == * Chae, Y. C., Angelin, A., Lisanti, S., Kossenkow, A. A., Speicher, K. D., Wang, H., Powers, J. F., Tischler, A. S., Pacak, K., Fliedner, S., Michalek, R. D., Karoly, E. D., Wallace, D. C., Languino, L. R., Speicher, D. W. and Altieri, D. C. (2013) Landscape of the mitochondrial Hsp90 metabolome in tumors. Nature Commun. 4:2139. * Caino, M. C., Chae, Y. C., Vaira, V., Ferrero, S., Nosotti, M., Martin, N. M., Weeraratna, A., O’Connell, M., Jernigan, D., Fatatis, A., Languino, L. R., Bosari, S., and Altieri, D. C. (2013) Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 123:2907-2920. * Chae, Y. C., Caino, M. C., Lisanti, S., Ghosh, J. C., Dohi, T., Danial, N. N., Villanueva, J., Ferrero, S., Vaira, V., Santambrogio, L., Bosari, S., Languino, L. R., Herlyn, M., and Altieri, D. C. (2012) Control of tumor bioenergetics and survival stress signaling by mitochondrial Hsp90s. Cancer Cell 22:331-344. * Siegelin, M. D., Dohi, T., Raskett, C. M., Orlowsky, G. M., Powers, C. M., Gilbert, C. A., Ross, A. H., Plescia, J., and Altieri, D. C. (2011) Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J. Clin. Invest. 121:1349-1360. * Mehrotra, S., Languino, L. R., Raskett, C. M., Mercurio, A. M., Dohi, T., andAltieri, D. C. (2010) IAP regulation of metastasis. Cancer Cell. 17:53-64. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Dario Altieri」の詳細全文を読む スポンサード リンク
|